We are testing a new medication, NVL-655, for patients with advanced ALK-positive non-small cell lung cancer and other solid tumors. The study aims to evaluate its safety and effectiveness, especially for those with resistance to current treatments.
Health conditions and diseases that the clinical trial is designed to study and treat.
Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK mutation is a type of lung cancer that occurs when there is a genetic alteration in the ALK gene, leading to uncontrolled cell growth. This condition is often associated with specific treatments targeting the ALK mutation.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
